Drug Trial Radar · NCT05253833
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Aug 12, 2022
Primary completion
Aug 13, 2024
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.
Conditions
- Gout
- Arthritis, Gouty
- Hyperuricemia
- Gout Chronic
Interventions
AR882 Dose 1Drug
Solid Oral Capsule
AR882 Dose 2Drug
Solid Oral Capsule
Allopurinol TabletDrug
Solid tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum urate (uric acid) (sUA) level < 5 mg/dL at month 3Time frame: 12 weeks
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Arthrosi Investigative Site (410)
Birmingham, Alabama
Arthrosi Investigative Site (403)
Phoenix, Arizona
Arthrosi Investigative Site (416)
Sun City, Arizona
Arthrosi Investigative Site (417)
Tucson, Arizona
Arthrosi Investigative Site (402)
Tampa, Florida
Arthrosi Investigative Site (404)
Boise, Idaho
Arthrosi Investigative Site (409)
Ann Arbor, Michigan
Arthrosi Investigative Site (406)
Greensboro, North Carolina
Arthrosi Investigative Site (408)
Myrtle Beach, South Carolina
Arthrosi Investigative Site (401)
Dallas, Texas
Arthrosi Investigative Site (201)
Auckland, New Zealand
Arthrosi Investigative Site (303)
Taichung, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.